DONAFENIB for Hepatocellular carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 33 adverse event reports in the FDA FAERS database where DONAFENIB was used for Hepatocellular carcinoma.
Most Reported Side Effects for DONAFENIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Therapy partial responder | 21 | 56.8% | 0 | 0 |
| Diarrhoea | 6 | 16.2% | 0 | 1 |
| Palmar-plantar erythrodysaesthesia syndrome | 6 | 16.2% | 0 | 1 |
| Rash | 6 | 16.2% | 0 | 1 |
| Abdominal pain | 5 | 13.5% | 0 | 0 |
| Hypertension | 5 | 13.5% | 0 | 0 |
| Nausea | 5 | 13.5% | 0 | 0 |
| Pyrexia | 5 | 13.5% | 0 | 0 |
| Vomiting | 5 | 13.5% | 0 | 0 |
Other Indications for DONAFENIB
Other Drugs Used for Hepatocellular carcinoma
ATEZOLIZUMAB (8,443)
BEVACIZUMAB (7,773)
LENVATINIB (5,384)
SORAFENIB (4,986)
CABOZANTINIB S-MALATE (2,670)
DURVALUMAB (1,255)
NIVOLUMAB (1,142)
REGORAFENIB (1,050)
TREMELIMUMAB\TREMELIMUMAB-ACTL (589)
PEMBROLIZUMAB (518)